Hirotsu Bio Science Inc.

Hirotsu Bio Science Inc. is a Japanese life science company established in 2016 with the aim of commercializing N-NOSE nematode cancer testing. It is headquartered in Chiyoda-ku, Tokyo, and is led by President & CEO Takaaki Hirotsu. Its business overview covers biological diagnostics research: research, development, and sale of cancer diagnostic tests utilizing C. elegans and C. elegans olfactory sensors. The company describes N-NOSE as the world's first cancer screening using biological diagnostic technology.

Hirotsu Bio Science Inc. was established in 2016 (headquartered in Akasaka, Minato-ku, Tokyo) with the aim of commercializing N-NOSE nematode cancer testing. Its origins trace to earlier research: a paper by Hirotsu revealing the involvement of the Ras-MAPK pathway in nematode olfaction was published in the British scientific journal Nature, and the first clinical study on nematode cancer scent detection by Takaaki Hirotsu was published in PLOS ONE. In 2017 the company implemented a capital increase through third-party share allotment, established the Central Research Laboratory, Fukuoka Research Laboratory, and Shikoku Analysis Center, and established the Australian firm Hirotsu Bio Australia Pty. Ltd. As of its company profile, it is headquartered at 22F The New Otani GARDEN COURT, 4-1 Kioicho, Chiyoda-ku, Tokyo, and its business overview is biological diagnostics research: research, development, and sale of cancer diagnostic tests utilizing C. elegans and C. elegans olfactory sensors.

The world's first cancer screening using biological diagnostic technology.

• N-NOSE

  The world's first cancer screening using biological diagnostic technology.

1. 1Hirotsu Bio Science Inc. | HIROTSUバイオサイエンスhbio.jp
2. 2Hirotsu Bio Science Inc. | HIROTSUバイオサイエンスhbio.jp
3. 3Hirotsu Bio Science Inc. | HIROTSUhbio.jp
4. 4HIROTSUバイオサイエンス | 線虫がん検査に関する世界最先端の線虫行動解析技術hbio.jp
5. 5Hirotsu Bio Science Inc.wikidata.org